Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
2011
NOTCH Signaling Is Required for Formation and Self-Renewal of Tumor-Initiating Cells and for Repression of Secretory Cell Differentiation in Colon Cancer
2010 StandoutNobel
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
2009
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
2012
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Antitumor activity of HER-2 inhibitors
2004
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
2005
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Aberrant intracellular metabolism of T‐ DM 1 confers T‐ DM 1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells
2017
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
2009
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
2010
EGFR Antagonists in Cancer Treatment
2008 Standout
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Bosutinib
2009
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Src kinases as therapeutic targets for cancer
2009
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
2006
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Cancer stem cells revisited
2017 Standout
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
2008 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
ErbBs in lung cancer
2008
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities
2011
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib
2012
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
EMT: 2016
2016 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Pancreatic Cancer
2010 Standout
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Emerging drugs for non-small-cell lung cancer
2007
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Bispecific antibodies: a mechanistic review of the pipeline
2019
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Crypt stem cells as the cells-of-origin of intestinal cancer
2008 StandoutNature
Identification of stem cells in small intestine and colon by marker gene Lgr5
2007 StandoutNature
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
2006
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2
2007
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
2008 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
2007
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
2010
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Covalent Modifiers: An Orthogonal Approach to Drug Design
2009
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
2006 StandoutNature
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Breast Cancer Treatment
2019 Standout
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
2006
Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
2010
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
2008
Current Status of Src Inhibitors in Solid Tumor Malignancies
2011
Modular repeat protein sculpting using rigid helical junctions
2020 StandoutNobel
Cooperation between VEGF and β3 integrin during cardiac vascular development
2006
The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
2008
Cancer Genome Landscapes
2013 StandoutScience
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Catalytic Asymmetric Protonation of Silyl Ketene Imines
2013 StandoutNobel
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
2010
Works of Jonathan Golas being referenced
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
2017
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
2004
Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity
2005
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice
2017
SKI-606, a Src/Abl Inhibitor withIn vivoActivity in Colon Tumor Xenograft Models
2005